Literature DB >> 10627827

Management of monocular congenital cataracts.

S R Lambert1.   

Abstract

Monocular congenital cataracts have been treated for the past two decades with early surgery, contact lens correction and patching of the unaffected eye. While an occasional patient has had a good visual outcome with this treatment regiment, the majority end up being legally blind in the aphakic eye. Intraocular lenses (IOLs) are increasingly being used as an alternative means of optically correcting aphakia during infancy. A growing body of literature suggests that an IOL correction is associated with an improved visual outcome and a relatively low incidence of post-operative complications. A monkey model has also been used to study the safety and feasibility of correcting aphakia in neonates with IOLs. These studies have revealed that the visual outcome is as good if not better with an IOL correction. A multicentre clinical trial, the Infant Aphakia Treatment Study (IATS), is being organised in the United States to critically compare an IOL and contact lens correction for infantile aphakia.

Entities:  

Mesh:

Year:  1999        PMID: 10627827     DOI: 10.1038/eye.1999.124

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  3 in total

Review 1.  Congenital and infantile cataract: aetiology and management.

Authors:  Wai H Chan; Susmito Biswas; Jane L Ashworth; I Christopher Lloyd
Journal:  Eur J Pediatr       Date:  2012-03-01       Impact factor: 3.183

2.  A pilot randomized trial of contrast-rebalanced binocular treatment for deprivation amblyopia.

Authors:  Eileen E Birch; Reed M Jost; Serena X Wang; Krista R Kelly
Journal:  J AAPOS       Date:  2020-10-16       Impact factor: 1.220

3.  Outcomes of secondary intraocular lens implantation in the Infant Aphakia Treatment Study.

Authors:  Deborah K VanderVeen; Carolyn D Drews-Botsch; Azhar Nizam; Erick D Bothun; Lorri B Wilson; M Edward Wilson; Scott R Lambert
Journal:  J Cataract Refract Surg       Date:  2021-02-01       Impact factor: 3.528

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.